Connect public, paid and private patent data with Google Patents Public Datasets

多糖凝胶制剂

Info

Publication number
CN101951879A
CN101951879A CN 200880123524 CN200880123524A CN101951879A CN 101951879 A CN101951879 A CN 101951879A CN 200880123524 CN200880123524 CN 200880123524 CN 200880123524 A CN200880123524 A CN 200880123524A CN 101951879 A CN101951879 A CN 101951879A
Authority
CN
Grant status
Application
Patent type
Prior art keywords
polysaccharide
inhibitor
gel
described
incorporating
Prior art date
Application number
CN 200880123524
Other languages
English (en)
Inventor
A·泰泽尔
C·S·马德
D·斯特姆普利斯
Original Assignee
阿勒根公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/26Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/721Dextrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738Cross-linked polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/042Gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/678Tocopherol, i.e. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/736Chitin; Chitosan; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/505Stabilizers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/02Making solutions, dispersions or lattices by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03Making solutions, dispersions or lattices by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075Macromolecular gels
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G
    • C08J2305/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUSE OF INORGANIC OR NON-MACROMOLECULAR ORGANIC SUBSTANCES AS COMPOUNDING INGREDIENTS
    • C08K5/00Use of organic ingredients
    • C08K5/04Oxygen-containing compounds
    • C08K5/05Alcohols; Metal alcoholates
    • C08K5/053Polyhydroxylic alcohols
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00Polymer mixtures characterised by other features
    • C08L2205/02Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group

Abstract

本文描述了包含至少一种多糖降解抑制剂的多糖凝胶制剂及其制备方法。本文描述的方法涉及步骤:提供至少一种多糖,并在所述多糖中掺入至少一种降解抑制剂。在一些实施方案中,所述掺入步骤包括1)在高水合状态下将所述至少一种抑制剂与所述至少一种多糖混合,从而将所述至少一种抑制剂封装于多糖网络中,以及2)水合所述多糖网络,从而控制释放动力学或终膨胀率。在另一个实施方案中,所述掺入步骤包括1)将所述至少一种抑制剂封装至一个生物相容的或可生物降解的容器中,以及2)将所述至少一种多糖和所述容器结合成一种凝胶制剂中。本文描述的多糖凝胶制剂可用于多种美容应用中。

Description

多糖凝胶制剂

[0001] 发明人

[0002] D.斯特姆普利斯、C. S.马德和A.泰泽尔

[0003] 相关专利申请的交叉引用

[0004] 本申请要求以2007年11月30日提交的美国临时专利申请60/991,473为优先权 基础,该临时申请的整个公开文本以引用的方式纳入本文。

技术领域

[0005] 整体上公开了用于增加多糖凝胶寿命的应用于美容和医疗中的制剂,以及制备其 和使用其的方法。

背景技术

[0006] 多糖是相对复杂的糖。多糖是由糖苷键连接在一起的许多单糖组成的聚合物。因 此,多糖是较大并经常有支链的大分子。多糖(尤其是透明质酸(HA))已被应用于美容和 医疗中。例如,这类聚合物已被用作软组织填充中的填充剂。

[0007] HA停留于细胞外空间,其作用是填充空间、稳定结构以及作为具有独特延展性物 理性质和极好生物相容性的细胞保护分子。HA基质有极端的粘弹性,而又保持高水平的水 合。在皮肤含水量和真皮组织中HA水平之间存在强相关。已知当人皮肤老化时,HA含量 和代谢发生改变。随着这些改变,皮肤的机械性质有明显劣化。在年轻皮肤和细胞间基质 中存在强HA网络之间似乎存在关联。

[0008] 不幸地是,非交联多糖链以及交联多糖链例如HA会通过不同通路降解(如酶降 解、自由基降解);从而限制该聚合物的体内寿命。因此,开发在体内降低天然分解速率并 增加产物持久性的方法和组合物是重要的。对通过抗降解而具有增加的寿命的多糖制剂仍 有未被满足的需求。

发明内容

[0009] 本文描述了在体内寿命增加或降解时间增加的多糖凝胶(例如透明质酸,HA)制 剂。该降解时间的增加由掺入作为降解抑制剂的分子提供。此外,本发明提供了用于封装 这些制剂以在体内维持延长的寿命或降解时间的方法。本发明还涉及可应用于药物或美容 用的凝胶制品。

[0010] 在一个实施方案中,本文描述了一种包含至少一种多糖和至少一种多糖降解抑制 剂的多糖凝胶制剂,所述多糖选自透明质酸、纤维素、壳聚糖、O-硫酸化的HA、葡聚糖、硫酸 葡聚糖、硫酸软骨素、硫酸皮肤素、硫酸角蛋白、肝素、硫酸肝素和藻酸盐,所述多糖降解抑 制剂选自糖胺聚糖(glycos iaminoglycan)、抗氧剂、黄酮类化合物、蛋白质、脂肪酸和它们 的结合物。在一个实施方案中,所述多糖是交联的。在一个实施方案中,所述至少一种多糖 为透明质酸。

[0011] 在一个实施方案中,所述糖胺聚糖选自肝素、硫酸肝素、硫酸皮肤素、硫酸软骨素、

4ο-硫酸化的透明质酸、亚麻仁苷(Linamarin)和苦杏仁苷(Amygdalin)。在另一个实施方 案中,所述糖胺聚糖为硫酸软骨素,并且以约1重量%至约40重量%的浓度存在。

[0012] 在一个实施方案中,抗氧剂选自抗坏血酸、褪黑激素、维生素C、维生素E和它们的 结合物。

[0013] 在一个实施方案中,所述黄酮类化合物选自四羟黄酮、芹菜素、福橘素、槲皮素、山 萘酚、杨梅素、漆黄素、异鼠李素、藿香黄酮醇、鼠李秦素、橙皮素、柚皮素、圣草酚、高圣草 素、紫杉醇、二氢槲皮素、二氢山萘酚、鞣酸、单宁、浓缩单宁、可水解单宁和它们的结合物。 在另一个实施方案中,所述黄酮类化合物为鞣酸,并且以约0.0001重量%至约1重量%的 浓度存在。

[0014] 在一个实施方案中,所述蛋白质为血清透明质酸酶抑制剂。在另一个实施方案中, 所述脂肪酸为饱和Cich22脂肪酸。

[0015] 在一个实施方案中,所述制剂还包含生物相容的或可生物降解的容器(vessel), 其中所述抑制剂在所述容器之中或者是所述容器的一部分,其中所述容器为脂质体、胶束 或聚合的小囊。在另一个实施方案中,所述抑制剂为所述制剂提供提高的流变性质,使得与 交联的多糖凝胶制剂相比给予所述制剂需要更小的挤出力。

[0016] 在一个实施方案中,本文描述了一种生产降解时间增加的多糖凝胶制剂的方法, 包括步骤:提供至少一种选自透明质酸、纤维素、壳聚糖、ο-酸化的HA、葡聚糖、硫酸葡聚 糖、硫酸软骨素、硫酸皮肤素、硫酸角蛋白、肝素、硫酸肝素和藻酸盐的多糖,并在所述多糖 中掺入至少一种选自糖胺聚糖、抗氧剂、黄酮类化合物、蛋白质和脂肪酸的多糖降解抑制 剂。

[0017] 在所述方法的一个实施方案中,掺入步骤包括1)在高水合状态下将所述抑制剂 与所述多糖混合,从而将所述抑制剂封装于多糖网络中,以及2)使所述多糖网络脱水,从 而控制释放动力学或终膨胀比。

[0018] 在所述方法的另一个实施方案中,在掺入所述至少一种多糖降解抑制剂前使用交 联剂交联所述至少一种多糖,所述交联剂选自1,4_ 丁二醇二缩水甘油醚(BDDE)、1,2-双 (2,3-环氧丙氧基)乙烯、1- (2,3-环氧丙基)-2,3-环氧环己烷和它们的结合物。

[0019] 在所述方法的一个实施方案中,所述掺入步骤包括1)将一种抑制剂封装至一个 生物相容的或可生物降解的容器中,以及2)将所述至少一种多糖和所述容器结合至一种 凝胶制剂中。

[0020] 在一个实施方案中,本文描述了一种降解时间增加的多糖凝胶制剂,其包含交联 的透明质酸和鞣酸,其中所述鞣酸以约0. 0001%至约的浓度存在。

[0021] 在一个实施方案中,本文描述了一种降解时间增加的多糖凝胶制剂,其包含交联 的透明质酸和硫酸软骨素,其中所述硫酸软骨素以约至约40%的浓度存在。

[0022] 本文还描述了包含多糖凝胶制剂、可药用载体和活性成分的药物组合物。在一个 实施方案中,所述活性成分选自抗痒剂、抗蜂窝组织剂、抗瘢痕剂、抗炎症剂、抗氧剂、维生 素、增湿剂和它们的结合物。

附图说明

[0023] 图1以曲线图示出使用量热试验得到的含硫酸软骨素A(CSA)的多糖凝胶的酶降解程度。

[0024] 图2以曲线图示出使用量热试验得到的含鞣酸(TA)的多糖凝胶的酶降解程度。

[0025] 图3以曲线图示出使用可溶性HA试验得到的有或无CSA的多糖凝胶的酶降解程度。

[0026] 图4以曲线图示出使用可溶性HA试验得到的有或无TA的多糖凝胶的酶降解程度。

[0027] 图5以曲线图示出CSA对多糖凝胶的挤出力的效应。 具体实施方式

[0028] 本文描述了通过掺入作为降解抑制剂的分子提供的在体内寿命增加或降解时间 增加的多糖凝胶(例如透明质酸,HA)制剂。在一些实施方案中,所述多糖凝胶是交联的。 此外,本发明还涉及用于封装这些制剂以在体内维持延长的寿命或降解时间的方法。本发 明还涉及可应用于药物或美容用的凝胶制品。

[0029] 本发明的一个方面涉及包含至少一种多糖和至少一种多糖降解抑制剂的多糖凝 胶制剂。本发明还涉及通过掺入降解抑制剂增加多糖凝胶的降解时间。“多糖”是指超过两 个单糖分子的聚合物,其中所述单糖可以相同或不同。本发明的多糖可以是交联的或非交 联的。本文使用的多糖可以为,但不限于HA、纤维素、壳聚糖、ο-硫酸化的HA、葡聚糖、硫酸 葡聚糖、硫酸软骨素、硫酸皮肤素、硫酸角蛋白、肝素、硫酸肝素和藻酸盐。

[0030] 抑制剂为通过靶向并中和具体降解机制如酶降解和自由基降解发挥作用的分子。 呈现抑制活性的分子包括但不限于糖胺聚糖(GAG)(例如肝素、硫酸肝素、硫酸皮肤素、硫 酸软骨素、ο-硫酸化的HA、亚麻仁苷和苦杏仁苷)、抗氧剂(例如抗坏血酸、褪黑激素、维生 素C和维生素E)、蛋白质(例如血清透明质酸酶抑制剂)和脂肪酸(例如饱和Cltl-C22脂肪 酸)。

[0031] 抑制剂的分子量一般比交联的多糖聚合物具有更小的数量级。由于抑制剂大小 较小且扩散性较高,它们在体内倾向于快速吸收,这有可能限制其性能。一种在体内增加 这类分子的局部半衰期的方法是,将它们化学接枝于所述多糖聚合物网络并且将它们同时 递送。该方法的一个缺点是,结合的分子可呈现比未结合的分子显著更低的活性。在本发 明的多糖凝胶制剂中,所述抑制剂的浓度可以是约0. 0001重量% -约99重量%,约0. 001 重量% -约75重量%,约0.01重量% -约60重量%,约1重量% -约50重量%,约1 重量% -约40重量%,约1重量% -约30重量%,约1重量% -约20重量%,约10重 量% -约20重量%,约20重量% -约30重量%,0. 0001重量% -约0. 01重量%,约0. 0001 重量% -约0. 1重量%,约0. 0001重量% -约1重量%,约0. 001重量% -约1重量%,约 0.01重量% -约1重量%,约1重量% -约10重量%。

[0032] 本发明的另一方面涉及一种生产降解减少的多糖凝胶制剂的方法,包括提供一种 多糖,并在所述多糖中封装一种降解抑制剂。

[0033] 非交联多糖链以及交联多糖链会通过不同途径降解(如酶降解、自由基降解),这 经常会限制该聚合物在体内的寿命。因此,开发在组织中降低天然分解速率并增加产物持 久性的方法是重要的。

[0034] 获得多糖持续时间增加的一种方法是,将抑制剂分子封装于多糖聚合物网络本身中或者至所述网络中的大容器中,这将使得降解抑制剂被局部(注入部位)、持续且可控的 释放。这还将能够避免天然降解机制。本发明的封装方法可在数周的时间向所述多糖聚合 物网络持续供应降解抑制剂。在另一些实施方案中,在数月的时间提供降解抑制剂的持续 供应。一种封装方法是,通过吸附或者通过封装过程将所述降解抑制剂封装于所述多糖聚 合物网络中。在后一种情况中,所述抑制剂被允许以高水合状态与所述多糖网络混合,然后 对所述网络脱水以控制所述释放动力学(例如所述聚合物的终膨胀率)。高水合状态对应 于低于约20mg/ml的HA浓度。

[0035] 可通过调节pH或者使所述多糖网络部分脱水而控制所述终膨胀率。可将所述收 缩的网络的大小调节成颗粒,与所述多糖凝胶混合并递送至所述注入部位。所述装载抑制 剂的多糖颗粒的缓慢再水合可提供其活性内容物的持续且可控的递送。

[0036] 本发明的另一方面涉及一种包含多糖和多糖降解抑制剂的多糖凝胶制剂,所述多 糖凝胶制剂还包含生物相容的或可生物降解的容器,其中所述抑制剂在所述容器之中或者 是所述容器的一部分。这类容器可以由非共价或共价连接的自组装分子例如脂质体、胶束 和聚合化小囊组成。

[0037] 脂质体是一种由一个或多个双层膜组成的小囊,所述双层膜由含混合脂质链的天 然来源的磷脂(例如卵磷脂酰乙醇胺)形成,或者由纯表面活性物质组分如二油酰磷脂酰 乙醇胺(DOPE)形成。脂质体(通常但非限定性地)包含一个水性溶液核心;包含非水性材 料的脂质结构称为胶束。胶束是分散于胶体流体中的表面活性分子的聚集体。水性溶液中 的典型胶束可形成聚集体,具有与周围溶剂接触的亲水“头部”区域,隔离所述胶束中央的 疏水“尾部”区域。这种类型的胶束被称为正相胶束(水包油胶束)。逆胶束的头部基团在 中央,尾部伸展向外(油包水胶束)。胶束通常近似球形,然而,还有可能为椭圆体、圆筒和 双层。胶束的形状和大小随其表面活性分子的分子几何结构以及溶液条件例如表面活性物 质浓度、温度、PH和离子强度变化。胶束的形成过程被称为胶粒形成,并根据脂质的多态性 形成多种脂质相性质的一部分。

[0038] 本发明的另一方面涉及一种制备降解减少的多糖凝胶制剂的方法,包括步骤:1) 提供一种多糖,2)将一种抑制剂掺入至一种生物相容的或可生物降解的容器中,以及3)将 所述多糖和容器结合成一种凝胶制剂中。该封装方法因此将所述抑制剂掺入至生物相容的 和可生物降解的容器中,所述容器可与所述多糖同时递送。这类容器可由非共价或共价连 接的自组装分子(例如胶束、脂质体和聚合的小囊)组成。本文使用的术语自组装描述这 样的过程,即其中已存在组分的无序体系形成一个有组织的结构或模式,无外部指导的情 况下在所述组分自身中形成特定的局部相互作用。

[0039] 所提出的制剂的另一优点是所述终产品流变性质的调整能力的增加。交联多糖凝 胶一般具有高粘度,需要相当大的力挤压通过细针。非交联多糖通常被用作润滑剂,以有利 于该挤压过程。然而,尤其在HA皮肤填充剂中,非交联HA对所述终产物在体内的持久性没 有贡献。事实上,越多交联HA被非交联HA替换以调整所述皮肤填充剂的流变性质(为获 得固定的总HA浓度),所述产品的降解抗性将会越低。另外,根据所提出的制剂,亦为降解 抑制剂的非交联GAG (例如硫酸软骨素、ο-硫酸化的透明质酸)可用于延长所述终产物的 寿命并改善其流变性质。

[0040] 本文描述的多糖可以是交联的或非交联的。交联剂可用于交联本说明书的多糖。

7所述交联剂可以是已知适合于多糖或其衍生物经由羟基交联的任意试剂。合适的交联剂包 括但不限于,例如1,4_ 丁二醇二缩水甘油醚(或者1,4_双(2,3_环氧丙氧基)丁烷或1, 4_双缩水甘油氧丁烷,它们通常都被称为BDDE)、1,2-双(2,3_环氧丙氧基)乙烯和1_(2, 3_环氧丙基)-2,3_环氧环己烷。本发明的范围还涵盖使用不止一种交联剂或不同交联剂。 在一个实施方案中,所述交联剂包含BDDE或者由BDDE组成。

[0041] 皮肤填充剂可用于治疗轻度至重度面部皱纹和褶皱如法令纹(那些从鼻子扩展 至嘴角的细纹)。皮肤填充剂可以为包括HA的凝胶植入物,HA是一种增强皮肤弹性的天然 复合糖,提供一种平滑且柔软的外表。它是生物相容的,可补充身体的天然HA——其随衰老 而耗尽。

[0042] 皮肤凝胶可经注射器注入至面部的真皮中部至深处。真皮是表皮之下的皮肤层, 含结缔组织、神经末梢、汗腺和油脂腺、以及血管。皮肤填充剂可通过提升及增加治疗区域 的皱纹和褶皱的体积而改善皮肤外表。

[0043] 本发明的另一方面涉及一种美容用的组合物,包含本发明的多糖凝胶制剂、美容 用的载体和活性成分。所述美容用的活性成分可包括但不限于抗氧剂、维生素和增湿剂。

[0044] 本文使用的形容词“美容用的”是指改善表皮外表或者遮盖缺陷。一般而言,美容 用的组合物可用于提高表皮的美观,而不是提高表皮的功能方面。更通常地,美容用的组合 物被配制用途健康和美学处理法,或者用于改变身体如角质表面的个性化外表,例如皮肤、 毛发、指甲等。

[0045] 本文使用的“可美容用载体”是指适合应用于角质表面或身体其他区域的物质。在 应用时,可美容用载体与皮肤和其他角膜表面基本上无不良反应。例如,美容用载体可采取 以下形式:脂肪乳剂或非脂肪乳剂、乳状悬液、油包乳剂或水包油型、洗剂、凝胶或胶冻剂、 胶状或非胶状水性溶液剂或油溶液剂、糊剂、气溶胶、可溶解片剂或者棒剂。

[0046] 本文使用的“制剂”和“组合物”可互换使用,是指在一块呈现给定目的的成分的 结合物。这类术语是本领域普通技术人员公知的。

[0047] 本文使用的“载体”、“惰性载体”和“可用的载体”可互换使用,是指可以与本发明 公开的多糖凝胶结合以提供所需组合物的载体。本领域普通技术人员应了解许多熟知的载 体可用于制备具体的治疗性药物和/或美容用组合物。

[0048] 本发明的另一方面涉及一种药物组合物,所述药物组合物包含所述多糖凝胶制 剂、药用载体和活性成分。本文使用的活性成分包括但不限于药物。药物一般可定义为用 于疾病的治疗、治愈、预防或诊断的或者用于另外增强身体健康或精神健康的化学物质。

[0049] 可以包括在本发明药物组合物中的活性成分的实例有抗痒剂、抗蜂窝组织剂、抗 瘢痕剂、抗炎症剂。抗痒剂可包括甲基磺酰甲烷、碳酸氢钠、炉甘石、尿囊素、高岭土、薄荷 油、茶树油和它们的结合物。抗蜂窝组织剂可包括福斯高林(forskolin)、黄嘌呤化合物,例 如但不限于咖啡因、茶碱、可可碱、氨茶碱和它们的结合物。抗瘢痕剂可包括IFN-Y、氟尿嘧 啶、乳酸/羟基乙酸共聚物、甲基化的聚乙二醇、聚乳酸、聚乙二醇和它们的结合物。抗炎症 剂可包括地塞米松、泼尼松龙、皮质酮、布地奈德、雌激素、柳氮磺吡啶、美沙拉嗪和它们的 结合物。

[0050] 多糖例如HA天然出现在身体的多种组织中,例如但不限于皮肤、软骨和玻璃体 液。因此,它十分适合于靶向这些组织的生物医学应用。HA可用于眼科手术中(即角膜移

8植、白内障手术、青光眼手术和修复视网膜脱离的手术)。HA还可用于治疗膝的骨关节炎。 这类治疗被称为黏弹性补充疗法,以注入膝关节中的过程给予,被认为可补充关节液的粘 度,从而润滑关节,缓冲关节并产生镇痛效应。还已经提出,HA对软骨细胞具有积极的生物 化学效应。最近提出可口服HA,但需证明其有效性。现如今,有一些初步的临床研究表明, 口服HA对骨性关节炎有积极效应。

[0051] 由于HA的高生物相容性极普遍存在于组织的细胞外基质中,它可在组织工程研 究中用作生物材料支架。在一些癌症中,HA水平与恶性和预后不良很好地相关。因此,HA 经常被用作前列腺和乳腺癌的肿瘤标记物。它还可以被用于监视疾病的进展。HA还可在手 术后使用,以诱导组织愈合,特别是在白内障手术后。现在的伤口愈合模型提出,更大的HA 聚合物出现于愈合的早期阶段以物理地为白细胞腾出空间,所述白血病介导免疫反应。

[0052] 药物组合物可任选地包含一种或多种试剂,例如但不限于乳化剂、湿润剂、甜味剂 或风味剂、渗透佐剂、防腐剂、缓冲剂、抗氧剂、黄酮类化合物。可用于本发明的药物组合物 中的渗透佐剂包括但不限于盐,例如乙酸钠、氯化纳、氯化钾;甘露醇或甘油;以及其他可 药用的渗透佐剂。可用于本文公开的药物组合物中的防腐剂包括但不限于苯扎氯铵、三 氯叔丁醇、硫柳汞、乙酸苯汞和硝酸苯汞。用于调节PH的多种缓冲剂和方法可用于制备 药物组合物,包括但不限于乙酸盐缓冲物、柠檬酸盐缓冲物、磷酸盐缓冲物和硼酸盐缓冲 物。类似地,可用于药物组合物中的抗氧剂是本领域中熟知的,包括例如焦亚硫酸钠、硫代 硫酸钠、乙酰半胱氨酸、丁羟茴醚和丁羟甲苯。黄酮类化合物是植物中出现的化合物,已知 它们具有不同的有利生物化学和抗氧剂效应。黄酮类化合物的亚类包括:黄酮、黄酮醇、 黄烷酮和黄烷酮醇。黄酮类化合物的实例包括:四羟黄酮、芹菜素、福橘素、槲皮素、山奈 酚、杨梅素、漆黄素、异鼠李素、藿香黄酮醇、鼠李秦素、橙皮素、柚皮素、圣草酚、高圣草素、 紫杉醇、二氢槲皮素、二氢山奈酚、鞣酸、单宁、浓缩单宁和可水解单宁。应理解,药理学领 域中已知的这些和其他物质可包括在本发明的药物组合物中。参见,例如Remington’ s Pharmaceutical Sciences Mac Publishing Company,Easton,PA,. 16 片反,1980。

[0053] 在下文使用实施例描述了本发明的一些优点,这些实施例记载了依照本文描述的 方法制备HA填充凝胶剂,依照现有技术制备HA填充凝胶剂以及针对这些样品进行的降解 试验。

[0054] 本文中使用的分子量(Mw)是指一个分子中原子的原子总重量。例如,甲烷(CH4) 的分子量是16. 043g/mol,原子量为碳=12. Ollg/mol,氢=1.008g/mol。道尔顿(Da)是重 量单位,等于12O重量的1/12,1百万Da可记作lMDa。

[0055] 实施例1

[0056] 依照本发明公开的内容制备HA填充凝胶剂

[0057] 将HA浓度为24mg/mL、交联度为约6%且G,为约180的1_5克多糖填充物 (JUVEDERM® 24HV, (Allergan Inc.,Irvine,California))与补充有 10_200mg硫酸软骨 素A (CSA-Mw = 5,000-120,OOODa)的1000 μ 1磷酸盐缓冲盐水(PBS)溶液(ρΗ约7)混合。 将所述混合物进行机械勻化。

[0058] 实施例2

[0059] 通过现有技术的方法制备HA填充凝胶剂

[0060] 将HA浓度为24mg/mL、交联度为约6%且G,为约180的1_5克多糖填充物(JUVEDERM® 24HV)与1000 u 1的PBS混合,使终HA浓度与实施例1中的相同。将所述 混合物进行机械勻化。

[0061] 实施例3

[0062] 依照本发明公开的内容制备另一种透明质酸填充凝胶剂

[0063] 将HA浓度为24mg/mL、交联度为约6%且G,为约170的1_5克基于HA的多糖填 充物(JUVEDERM® 30)与补充有 l_20mg 鞣酸(TA-MW = 800-4, OOODa)的 50 yl 的 PBS 溶 液(PH约7)混合。将所述混合物进行机械勻化。

[0064] 实施例4

[0065] 通过现有技术的方法制备另一种透明质酸填充凝胶剂将HA浓度为24mg/mL、交联 度为约6%且G,为约170的1-5克基于HA的多糖填充物(JUVEDERM® 30)与50 yl的 PBS混合,使终HA浓度与实施例3中的相同。将所述混合物进行机械勻化。

[0066] 实施例5

[0067] 依照本发明公开的内容制备透明质酸填充凝胶剂

[0068] 将1克透明质酸钠纤维(NaHA,Mw = 0. 5_3MDa)与5_10g的1 %氢氧化钠溶液混 合,并放置所述混合物1-5小时以进行水合。

[0069] 将50-200毫克1,4_ 丁二醇二缩水甘油醚(BDDE)加入至NaHA凝胶剂中,并将所 述混合物进行机械勻化。

[0070] 然后,将所述混合物至于40-70°C的烤箱中1-4小时。

[0071] 将所形成的交联水凝胶用当量的氢氯酸(HC1)中和并在PBS(pH ^ 7)中膨胀。

[0072] 加入10-200毫克CSA (Mw = 5,000-120,OOODa),并将所述水凝胶进行机械勻化。

[0073] 实施例6

[0074] 依照现有技术的方法制备透明质酸(HA)填充凝胶剂

[0075] 将1克NaHA (Mw = 0. 5_3MDa)与5_10g的1 %氢氧化钠溶液混合,并放置所述混合 物1-5小时以进行水合。

[0076] 将50-200毫克BDDE (与实施例5中HA :交联剂摩尔比相同)加入至NaHA凝胶剂 中,并将所述混合物进行机械勻化。

[0077] 然后,将所述混合物至于40-70°C的烤箱中1-4小时。

[0078] 将所形成的交联水凝胶用当量的氢氯酸(HC1)中和并在PBS(pH ^ 7)中膨胀,使 得终HA浓度与实施例5中的相同。将所得到的水凝胶进行机械勻化。

[0079] 实施例7

[0080] 酶降解研究(量热试验)

[0081] 使用Morgan-Elson量热测定评估实施例1和2中制备的HA填充凝胶剂对酶降解 的抗性。将该测定用于在酶降解之前和之后估计HA链的平均分子量。

[0082] 将透明质酸酶(0. l-10mg)加入至HA样品中,在37°C下维持10-250分钟,然后加 入0. lml的0. 8M四硼酸钾溶液并在100°C下加热10分钟。将所述样品补充3ml的10重量% 对二甲氨基苯甲醛的乙酸溶液,并在37°C下孵育10-120分钟。将降解之后和之前585nm下 光密度(0D)的变化用于对每个样品中的降解程度进行定量。

[0083] 显示于图1的在依照本发明的方法和依照现有技术制备的填充凝胶剂上进行的 测量结果(酶降解试验结果(量热测定))表明,通过本发明公开的方法制备的凝胶剂的0D值(实施例1 :0. 774-25. 184mg/ml CSA)低于通过现有技术的方法制备的凝胶剂的0D值 (实施例2 :Omg/ml CSA)。再者,0D值的降低与CSA浓度成比例。由于0D值代表了降解的 程度,这些结果表明依照本发明的方法制备的凝胶剂呈现比依照现有技术方法制备的凝胶 剂高3-75%的酶降解抗性。

[0084] 类似于补充CSA的凝胶剂的情况,如图2中所示,通过本发明的方法制备的补充有 TA的凝胶剂的0D值(实施例3 :0. 063-1. 000mg/mL TA)低于通过现有技术的方法制备的 凝胶剂的0D值(实施例4 :0mg/mL TA)。再者,0D值的降低与TA浓度成比例。由于0D值 代表了降解的程度,这些结果表明依照本发明的方法制备的凝胶剂呈现比依照现有技术方 法制备的凝胶剂高15-90%的酶降解抗性。还可以看出,TA具有比CSA更高的抑制活性,这 是因为TA以低1个数量级的量获得与CSA相同的抑制。

[0085] 实施例8

[0086] 酶降解研究(可溶性HA测定)

[0087] 为了进一步评估实施例1和2中制备的HA填充凝胶剂对酶降解的抗性,使用了基 于SEC-MALS (体积排阻多角度光散射)的可溶性HA测定。可使用该测定通过评估每个样 品中含有的可溶性HA的百分数(定义为可通过0. 2-1. Oym滤器的凝胶部分)对降解进行 定量。降解之前和之后可溶性HA的量变化可用于定量每个样品中的降解程度。

[0088] 使用装配有Wyatt光散射和折射指数单元的Agilent体积排阻色谱系统进行 SEC-MALS试验。将透明质酸酶(0. l-10mg)加入至HA样品中,在37°C下维持10-250分钟, 然后加入0. lml 0.8M四硼酸钾溶液并在100°C下加热10分钟。将所述样品于PBS中稀释, 过滤通过0. 2-1. 0 u m滤器并注入至SEC-MALS系统中。酶解之前和之后可溶性HA含量以 及它们的差显示于图3中。

[0089] 显示于图3中的结果(酶降解试验结果(SEC-MALS测定))表明,不含CSA的样品 的酶降解后的可溶性HA含量显著更高。CSA和非CSA样品之间可溶性HA增加的这种差异 与量热降解测定中得到的结果一致,并表明依照本发明的方法制备的凝胶剂显示比依照现 有技术制备的凝胶剂更高的降解抗性。

[0090] 类似于补充CSA的凝胶剂的情况,通过本说明书的方法制备的补充TA的凝胶剂的 可溶性HA含量(实施例3 :0. 063-1. 000mg/mL TA)低于通过现有技术的方法制备的凝胶剂 的可溶性HA含量(实施例4:0mg/mL TA)。这些结果与总结于图4中的量热方法相符。再 者,还可以看出,TA的抑制活性比CSA高1个数量级。

[0091] 实施例9

[0092] 连续挤压力试验

[0093] 为了评估实施例5和6中制备的透明质酸填充凝胶剂的流变性质,在每个样品上 进行了连续挤压力试验。挤压力试验可用于确定CSA是否可通过作为润滑剂而有利于所述 挤压过程。

[0094] 使用带有30G针头的5ml注射器在Ins tron仪器上进行挤压力试验。将0. 5ml 每个样品以50mm/分钟的恒定速率挤出。所记录的力的峰值是挤压容易程度的定量。两个 样品的压力与压缩伸长的函数绘于图5中。

[0095] 图5中的结果表明,对通过本文描述的方法制备的凝胶剂记录到的挤压力低于对 通过现有技术的方法制备的凝胶剂的记录到的挤压力。挤压力的这种差异是流动时的凝胶硬度差异的特征,并且表明通过本文描述的方法制备的凝胶剂中含有的CSA发挥有利于流 动的润滑剂的功能。

[0096] 除非另有指出,在说明书及权利要求书中使用的表示成分数量、性质例如分子量、 反应条件等的所有数值,应理解为在所有情形中都以词语“约”进行修饰。因而,除非另有 指明,说明书及所附权利要求书中所提到的数值参数均为约数,其可随本发明想要获得的 所需性质而变。至少,并不试图限制将等同原则用于解释权利要求书的范围,每个数值参 数至少应根据所报道的有意义的数字的值,并应用常规的近似方法来理解。尽管陈述本发 明的宽泛范围的数值范围和参数为约数,但对具体实施例中提到的数值作尽可能精确的报 道。但是,任何数值都内在地包含一定的由它们各自的测试过程所存在的标准偏差而必然 导致的误差。

[0097] 在描述本发明时(尤其是在所附的权利要求书中)使用的词语“一”、“一个”、“该” 以及类似的指代,应理解为包括单个和多个,除非文中另有指出,或与上下文意思明显相 悖。文中引述值的范围仅意在作为一种对落在所述范围内的每个单独值各个提及的简便方 法。除非文中另有指出,每个单独值均被纳入说明书中,如同单独引述一般。文中所述的所 有方法可以任何合适的顺序实施,除非文中另有指出或与上下文意思明显相悖。文中使用 的任何及所有实例,或示例性语言(如,“例如”)仅意在更好地阐明本发明,并不对本发明 所要求保护的范围进行限制。说明书中任何语言均不应被理解为表示对于实施本发明所必 需但不要求保护的要素。

[0098] 文中所公开的发明的可选择要素或实施方案的分组不应被理解为限制性的。每个 组要素可单个被提及和被要求,或者与该组内的其它要素或文中出现的其它要素的任意组 合的形式被提及和被要求。可以预见,出于简便和/或可专利性的原因,一个或多个要素可 被囊括于组内,或自组内删除。当出现任何这类囊括或删除时,说明书应被认为包含所修改 的组,从而满足随附权利要求书中使用的所有马库什组的书面说明。

[0099] 本发明的某些实施方案在文中作了描述,包括发明人已知的实施本发明的最佳方 式。当然,所述实施方案的变型对本领域技术人员而言,在其阅读前面的说明后将会变得很 清楚。发明人预期本领域技术人员可以适当地使用所述变型,并且发明人也想使本发明以 与文中所具体描述的不同的方式来实施。因此,本发明包括适用的法律所许可的所附权利 要求中记载的主题的所有变化及等同方式。此外,上述要素在其所有可能的变型中的任意 组合均涵盖于本发明之内,除非文中另有指出或与上下文含义明显相悖。

[0100] 此外,说明书通篇提到了多篇专利及出版物文献。上述文献及出版物中的每一篇 的全文均通过引用的方式纳入本说明书。

[0101] 最后,应理解的是,文中所公开的发明的实施方案是本发明原理的示例说明。可使 用的其它变化方案也在本发明的范围内。因此,例如,但不限于,可根据本文教导而使用本 发明的替代构型。因而,本发明不限于具体示出及描述的方案。

[0102] 本文公开的具体实施方案可使用语言“由......组成”或“基本由......组成”

在权利要求书中进一步进行限制。当用于权利要求中时,不管是初始提交或者是后加的每

次修改时,及物术语“由......组成”不包括权利要求中未指定的任何要素、步骤或成分。

及物术语“基本由......组成”将权利要求的范围限制到指定的物质或步骤,以及那些不

重大影响基本特征和新特征的物质或步骤。所要求的本发明的实施方案在本文中固有地或明确地被记载或实现。

Claims (20)

  1. 一种包含至少一种多糖和至少一种多糖降解抑制剂的多糖凝胶制剂,所述多糖选自透明质酸、纤维素、壳聚糖、o‑硫酸化的HA、葡聚糖、硫酸葡聚糖、硫酸软骨素、硫酸皮肤素、硫酸角蛋白、肝素、硫酸肝素和藻酸盐,所述多糖降解抑制剂选自糖胺聚糖、抗氧剂、黄酮类化合物、蛋白质、脂肪酸和它们的结合物。
  2. 2.权利要求1的制剂,其中所述多糖是交联的。
  3. 3.权利要求1的制剂,其中所述至少一种多糖为透明质酸。
  4. 4.权利要求1的制剂,其中所述糖胺聚糖选自肝素、硫酸肝素、硫酸皮肤素、硫酸软骨 素、ο-硫酸化的透明质酸、亚麻仁苷和苦杏仁苷。
  5. 5.权利要求4的制剂,其中所述糖胺聚糖为硫酸软骨素。
  6. 6.权利要求5的制剂,其中所述硫酸软骨素以约1重量%至约40重量%的浓度存在。
  7. 7.权利要求1的制剂,其中所述抗氧剂选自抗坏血酸、褪黑激素、维生素C、维生素E和 它们的结合物。
  8. 8.权利要求1的制剂,其中所述黄酮类化合物选自四羟黄酮、芹菜素、福橘素、槲皮素、 山萘酚、杨梅素、漆黄素、异鼠李素、藿香黄酮醇、鼠李秦素、橙皮素、柚皮素、圣草酚、高圣草 素、紫杉醇、二氢槲皮素、二氢山萘酚、鞣酸、单宁、浓缩单宁、可水解单宁和它们的结合物。
  9. 9.权利要求8的制剂,其中所述黄酮类化合物为鞣酸。
  10. 10.权利要求9的制剂,其中所述鞣酸以约0. 0001至约1重量%的浓度存在。
  11. 11.权利要求1的制剂,其中所述蛋白质为血清透明质酸酶抑制剂。
  12. 12.权利要求1的制剂,其中所述脂肪酸为饱和Cich22脂肪酸。
  13. 13.权利要求1的制剂,还包含生物相容的或可生物降解的容器,其中所述抑制剂在所 述容器之中或者是所述容器的一部分,其中所述容器为脂质体、胶束或聚合的小囊。
  14. 14.权利要求1的制剂,其中所述抑制剂为所述制剂提供提高的流变性质,使得与交联 的多糖凝胶制剂相比给予所述制剂需要更小的挤出力。
  15. 15. 一种制备降解时间增加的多糖凝胶制剂的方法,包括步骤:提供至少一种选自透明质酸、纤维素、壳糖、ο-硫酸化的HA、葡聚糖、硫酸葡聚糖、硫酸 软骨素、硫酸皮肤素、硫酸角蛋白、肝素、硫酸肝素和藻酸盐的多糖,并在所述多糖中掺入至 少一种选自糖胺聚糖、抗氧剂、黄酮类化合物、蛋白质和脂肪酸多糖降解的抑制剂。
  16. 16.权利要求15的方法,其中所述掺入步骤包括1)在高水合状态下将所述至少一种抑 制剂与所述至少一种多糖混合,从而将所述至少一种抑制剂封装于多糖网络中,以及2)水 合所述多糖网络,从而控制释放动力学或终膨胀率。
  17. 17.权利要求15的方法,其中在掺入所述至少一种多糖降解抑制剂前使用交联剂交联 所述至少一种多糖,所述交联剂选自1,4_ 丁二醇二缩水甘油醚(BDDE)、1,2_双(2,3_环氧 丙氧基)乙烯、1- (2,3-环氧丙基)-2,3-环氧环己烷和它们的结合物。
  18. 18.权利要求15的方法,其中所述掺入步骤包括1)将所述至少一种抑制剂封装至一个 生物相容的或可生物降解的容器中,以及2)将所述至少一种多糖和所述容器结合成一种 凝胶制剂中。
  19. 19. 一种降解时间增加的多糖凝胶制剂,包含交联的透明质酸和鞣酸,其中所述鞣酸以 约0. 0001%至约的浓度存在。
  20. 20. 一种降解时间增加的多糖凝胶制剂,包含交联的透明质酸和硫酸软骨素,其中所述硫酸软骨素以约至约40%的浓度存在。
CN 200880123524 2007-11-30 2008-11-24 多糖凝胶制剂 CN101951879A (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US99147307 true 2007-11-30 2007-11-30
US60/991,473 2007-11-30
US12276167 US8394782B2 (en) 2007-11-30 2008-11-21 Polysaccharide gel formulation having increased longevity
US12/276,167 2008-11-21
PCT/US2008/084515 WO2009073437A1 (en) 2007-11-30 2008-11-24 Polysaccharide gel formulation

Publications (1)

Publication Number Publication Date
CN101951879A true true CN101951879A (zh) 2011-01-19

Family

ID=40676371

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200880123524 CN101951879A (zh) 2007-11-30 2008-11-24 多糖凝胶制剂

Country Status (9)

Country Link
US (4) US8394782B2 (zh)
JP (1) JP2011505362A (zh)
KR (1) KR101554758B1 (zh)
CN (1) CN101951879A (zh)
CA (1) CA2706880A1 (zh)
EP (2) EP3047844A1 (zh)
ES (1) ES2568781T3 (zh)
RU (1) RU2010125704A (zh)
WO (1) WO2009073437A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102973592A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗糖尿病药物中的应用
CN104083396A (zh) * 2014-06-27 2014-10-08 牟国营 角膜表面保护剂及其制备方法和应用
CN104188819A (zh) * 2014-09-25 2014-12-10 山西医科大学 一种透明质酸分散的橙皮素纳米爽肤水及其制备方法
CN104083396B (zh) * 2014-06-27 2017-07-25 牟国营 角膜表面保护剂及其制备方法和应用

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
CA2687990A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Cross-linked collagen and uses thereof
US20120071437A1 (en) 2007-07-30 2012-03-22 Allergan, Inc. Tunable crosslinked polysaccharide compositions
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US8318695B2 (en) * 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8697044B2 (en) * 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
KR101577471B1 (ko) 2007-11-16 2015-12-14 알러간, 인코포레이티드 자색반병의 치료를 위한 조성물 및 방법
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
WO2010006376A1 (en) * 2008-07-18 2010-01-21 Novasel Australia Pty Ltd Compositions comprising tea tree oil and methods for the prevention and treatment of cancer
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US20110118206A1 (en) * 2008-08-04 2011-05-19 Allergan Industrie, Sas Hyaluronic acid based formulations
EP3184552A1 (en) 2008-09-02 2017-06-28 Tautona Group LP Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
JP4885245B2 (ja) * 2009-01-15 2012-02-29 日本航空電子工業株式会社 Rdコンバータ及び角度検出装置
US8846640B2 (en) 2009-08-27 2014-09-30 Fidia Farmaceutici S.P.A. Viscoelastic gels as novel fillers
US20110172180A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
KR101764451B1 (ko) 2010-03-12 2017-08-02 알러간 인더스트리 에스에이에스 피부 상태 개선을 위한 히알루론안 폴리머 및 만니톨을 포함하는 유체 조성물
ES2585388T3 (es) 2010-03-22 2016-10-05 Allergan, Inc. Hidrogeles reticulados de polisacárido y proteína-polisacárido para aumento de tejido blando
RU2528443C2 (ru) * 2010-06-25 2014-09-20 Суити КИМУРА Способ снижения содержания акриламида в обработанном пищевом продукте
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US20130196944A1 (en) * 2010-08-19 2013-08-01 Merz Pharma Gmbh & Co. Kgaa Filler composition comprising beta-glucans
FR2968306B1 (fr) * 2010-12-06 2014-02-28 Teoxane Procede de preparation d'un gel reticule
WO2012090224A1 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
US9464222B2 (en) * 2011-03-09 2016-10-11 Baker Hughes Incorporated Well fluid and method of servicing a well
US20140315854A1 (en) * 2011-05-12 2014-10-23 Gnosis S.P.A. Biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof
CN102805880A (zh) * 2011-05-31 2012-12-05 上海国睿生命科技有限公司 一种组织工程凝胶支架材料及其制备方法和用途
EP3175840A1 (en) * 2011-12-08 2017-06-07 Allergan, Inc. Dermal filler compositions
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
KR20140072008A (ko) 2011-06-03 2014-06-12 알러간, 인코포레이티드 항산화제를 포함하는 피부 충전제 조성물
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
CA2844785A1 (en) * 2011-08-25 2013-02-28 Allergan, Inc. Dermal filler compositions including antioxidants
EP2543357A1 (en) 2011-07-07 2013-01-09 Holy Stone Healthcare Co.,Ltd. Composition for use in treating and preventing inflammation related disorder
FR2978664B1 (fr) 2011-08-04 2014-01-10 Petcare Innovation Composition antiseptique
CN104105474A (zh) * 2011-09-14 2014-10-15 阿勒根公司 用于细纹治疗的真皮填充剂组合物
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
CA2876070A1 (en) 2012-06-15 2013-12-19 Merz Pharma Gmbh & Co. Kgaa Method of preparing a composition based on hyaluronic acid
WO2014055895A1 (en) 2012-10-05 2014-04-10 Allergan, Inc. Injectable device and method for sculpting, augmenting or correcting facial features such as the chin
FR3002452B1 (fr) 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
CA2905988A1 (en) 2013-03-14 2014-09-25 Church & Dwight Co., Inc. Aqueous lubricant composition
EP3101064A4 (en) 2014-01-31 2017-09-13 Seikagaku Kogyo Co Ltd Diamine crosslinking agent, acidic polysaccharide crosslinked body, and medical material
CN105327356A (zh) * 2014-08-11 2016-02-17 南京理工大学 一种磁性多聚糖纳米凝胶材料的制备方法
EP3040117A1 (en) * 2014-12-29 2016-07-06 Galderma S.A. Ether cross-linked chondroitin sulfate hydrogels and their use for soft tissue applications

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2128827A (en) 1938-03-09 1938-08-30 Frank B Killian Method and apparatus for manufacturing thin rubber articles
CA807629A (en) 1966-06-30 1969-03-04 Eigen Edward Lotion and detergent compositions
JPS4838158B1 (zh) 1970-10-05 1973-11-15
CA949965A (en) 1971-12-03 1974-06-25 Robert H. Marchessault Method of preparing cross-linked starch and starch derivatives
US3949073A (en) 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
US4060081A (en) 1975-07-15 1977-11-29 Massachusetts Institute Of Technology Multilayer membrane useful as synthetic skin
US4233360A (en) 1975-10-22 1980-11-11 Collagen Corporation Non-antigenic collagen and articles of manufacture
CA1073360A (en) 1975-10-22 1980-03-11 John R. Daniels Non-antigenic collagen and articles of manufacture
JPS581933Y2 (zh) 1979-04-23 1983-01-13
US4279812A (en) 1979-09-12 1981-07-21 Seton Company Process for preparing macromolecular biologically active collagen
JPS6052129B2 (zh) 1979-10-04 1985-11-18 Kureha Chemical Ind Co Ltd
US4486416A (en) * 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
US4424208A (en) 1982-01-11 1984-01-03 Collagen Corporation Collagen implant material and method for augmenting soft tissue
US4582640A (en) 1982-03-08 1986-04-15 Collagen Corporation Injectable cross-linked collagen implant material
US4501306A (en) 1982-11-09 1985-02-26 Collagen Corporation Automatic syringe filling system
US4716154A (en) 1984-06-08 1987-12-29 Pharmacia Ab Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute
CA1263647A (en) 1984-07-23 1989-12-05 Belder Anthony Norman De Method of preventing adhesion between body tissues, means for preventing such adhesion, and process for producing said means
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4605691A (en) 1984-12-06 1986-08-12 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4772419A (en) 1985-03-01 1988-09-20 Pharmacia Ab Shaped article and processes for its preparation
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US4642117A (en) 1985-03-22 1987-02-10 Collagen Corporation Mechanically sheared collagen implant material and method
US4803075A (en) 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
FR2608456B1 (fr) 1986-12-18 1993-06-18 Mero Rousselot Satia Microcapsules a base de gelatine et de polysaccharides et leur procede d'obtention
US5385938B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
FR2623167B2 (fr) 1987-08-14 1992-08-07 Genus Int Perfectionnement aux articles munis d'articulations elastiques se rigidifiant lors de leur mise en tension
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
JPH01113401A (en) 1987-10-27 1989-05-02 Mitsubishi Rayon Co Ltd Stabilization of aqueous hyaluronic acid solution
DE68929241T2 (de) 1988-05-13 2001-04-05 Fidia Spa Vernetzte Carboxypolysaccharide
US5643464A (en) 1988-11-21 1997-07-01 Collagen Corporation Process for preparing a sterile, dry crosslinking agent
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5565519A (en) 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5009013A (en) 1988-11-30 1991-04-23 Wiklund Henry W Device in machines for the marking of workpieces
JPH0552808B2 (zh) 1989-02-15 1993-08-06 Chisso Corp
ES2075148T3 (es) 1989-05-19 1995-10-01 Hayashibara Biochem Lab Acido alfa-glicosil-l-ascorbico, y su preparacion y usos.
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
EP0416250A3 (en) 1989-08-01 1991-08-28 The Research Foundation Of State University Of New York N-acylurea and o-acylisourea derivatives of hyaluronic acid
CA2023922A1 (en) 1989-09-05 1991-03-06 James M. Curtis Method of manufacturing an implantable article provided with a micropillared surface
JP2832848B2 (ja) 1989-10-21 1998-12-09 株式会社林原生物化学研究所 結晶2―O―α―D―グルコピラノシル―L―アスコルビン酸とその製造方法並びに用途
US5314874A (en) 1991-04-19 1994-05-24 Koken Co., Ltd. Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen
US4996787A (en) * 1990-05-29 1991-03-05 Jack N. Holcomb SigSauer pistol with concealed radio transmitter
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5143724A (en) 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5246698A (en) 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
JP3115625B2 (ja) 1991-03-30 2000-12-11 帝國製薬株式会社 リドカイン含有外用貼付剤
JP3267972B2 (ja) 1992-02-28 2002-03-25 コラーゲン コーポレイション 高濃度均質化コラーゲン組成物
JP3698720B2 (ja) 1992-07-03 2005-09-21 ミニステロ・デル・ウニヴェルシタ・エ・デッラ・リチェルカ・シエンティフィカ・エ・テクノロジカ 相互貫入ポリマー網(ipn)におけるヒアルロン酸およびその誘導体
DE69403062T2 (de) 1993-01-20 1997-08-14 Squibb & Sons Inc Fasern
EP0784487A1 (en) 1993-03-19 1997-07-23 Medinvent A composition and a method for tissue augmentation
US5531716A (en) 1993-09-29 1996-07-02 Hercules Incorporated Medical devices subject to triggered disintegration
DE4339486A1 (de) 1993-11-19 1995-05-24 Erwin Backhaus Mittel zur Verzögerung des Alterungsprozesses der Haut
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
CA2146090C (en) 1994-05-10 1998-11-24 Mark E. Mitchell Apparatus and method of mixing materials in a sterile environment
US5616689A (en) 1994-07-13 1997-04-01 Collagen Corporation Method of controlling structure stability of collagen fibers produced form solutions or dispersions treated with sodium hydroxide for infectious agent deactivation
EP0711794B1 (en) 1994-10-18 2001-01-17 Ethicon Inc. Injectable liquid copolymers for soft tissue repair and augmentation
US20050186673A1 (en) 1995-02-22 2005-08-25 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material, and method
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
FR2733427B1 (fr) 1995-04-25 2001-05-25 W K Et Associes Compositions biphasiques injectables renfermant de l'acide hyaluronique, notamment utiles en chirurgies reparatrice et esthetique
FR2733426B1 (fr) 1995-04-25 1997-07-18 Debacker Yves Dispositif medical pour le comblement des deformations du volume de la peau telles que rides et cicatrices par injection de 2 formes physico-chimiques differentes d'un polymere biologique
US6214331B1 (en) 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US5571503A (en) 1995-08-01 1996-11-05 Mausner; Jack Anti-pollution cosmetic composition
US6063405A (en) 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
EP0781547B1 (en) 1995-12-22 2002-04-17 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
WO1998017285A1 (en) 1996-10-17 1998-04-30 Fidia S.P.A. Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
FR2759576B1 (fr) 1997-02-17 1999-08-06 Corneal Ind Implant de sclero-keratectomie pre-descemetique
FR2759577B1 (fr) 1997-02-17 1999-08-06 Corneal Ind Implant de sclerectomie profonde
US5935164A (en) 1997-02-25 1999-08-10 Pmt Corporaton Laminated prosthesis and method of manufacture
FR2764514B1 (fr) 1997-06-13 1999-09-03 Biopharmex Holding Sa Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
US7192984B2 (en) 1997-06-17 2007-03-20 Fziomed, Inc. Compositions of polyacids and polyethers and methods for their use as dermal fillers
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
EP1041996A4 (en) 1997-12-22 2003-05-14 Human Genome Sciences Inc Keratinocyte growth factor-2 formulations
FR2780730B1 (fr) 1998-07-01 2000-10-13 Corneal Ind Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique
DE69925733T2 (de) 1998-07-06 2006-03-16 Fidia Farmaceutici S.P.A., Abano Terme Hyaluronsäureamide und ihre derivate und ein verfahren zu deren herstellung
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
JP2002529549A (ja) 1998-11-11 2002-09-10 アクイジティオ ソチエタ ペル アツィオニ カルボキシル化多糖の架橋方法
US6387382B1 (en) 1998-11-23 2002-05-14 Axiom Laboratories, Inc. Water-proof, respirable, skin barrier composition
DK172900B1 (da) 1998-12-18 1999-09-27 Per Julius Nielsen Præparat samt kit til brug ved intraoculære operationer
GB9902652D0 (en) 1999-02-05 1999-03-31 Fermentech Med Ltd Process
US6767928B1 (en) 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6521223B1 (en) 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
US6682760B2 (en) 2000-04-18 2004-01-27 Colbar R&D Ltd. Cross-linked collagen matrices and methods for their preparation
KR20010096388A (ko) 2000-04-19 2001-11-07 진세훈 귀두확대성형재료 및 이 재료를 이용한 귀두의 확대시술방법
FR2811671B1 (fr) 2000-07-17 2003-02-28 Corneal Ind Hydrogel de polymere(s), resistant a la biodegration, preparation et utilisation a titre de support de regeneration tissulaire
FR2811996B1 (fr) 2000-07-19 2003-08-08 Corneal Ind Reticulation de polysaccharide(s), preparation d'hydrogel(s) ; polysaccharide(s) et hydrogel(s) obtenus,leurs utilisations
WO2002009792A1 (en) 2000-07-28 2002-02-07 Anika Therapeutics, Inc. Bioabsorbable composites of derivatized hyaluronic acid
US6620196B1 (en) 2000-08-30 2003-09-16 Sdgi Holdings, Inc. Intervertebral disc nucleus implants and methods
US6773723B1 (en) 2000-08-30 2004-08-10 Depuy Acromed, Inc. Collagen/polysaccharide bilayer matrix
JP4187917B2 (ja) 2000-09-08 2008-11-26 新田ゼラチン株式会社 組織再生マトリックス用グリコサミノグリカン−コラーゲン複合体の製造方法
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
JP2004510730A (ja) 2000-10-06 2004-04-08 ヤゴテック アーゲー 非経口的投与可能な制御放出微粒子調製物
KR100375299B1 (ko) 2000-10-10 2003-03-10 주식회사 엘지생명과학 히알루론산의 가교결합형 아마이드 유도체와 이의 제조방법
US6599627B2 (en) 2000-12-13 2003-07-29 Purdue Research Foundation Microencapsulation of drugs by solvent exchange
US6979440B2 (en) 2001-01-29 2005-12-27 Salvona, Llc Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
US6852255B2 (en) 2001-05-02 2005-02-08 Industrial Technology Research Institute Method for producing water-insoluble polysaccharides
EP1423081A4 (en) 2001-06-25 2005-05-25 Depuy Int Ltd Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints
WO2003007782A3 (en) 2001-06-29 2003-04-24 Crisofo Peralta Caseres Biodegradable injectable implants and related methods of manufacture and use
US6749841B2 (en) 2001-07-26 2004-06-15 Revlon Consumer Products Corporation Stabilized aqueous acidic antiperspirant compositions and related methods
US20060189516A1 (en) 2002-02-19 2006-08-24 Industrial Technology Research Institute Method for producing cross-linked hyaluronic acid-protein bio-composites
JP4230135B2 (ja) 2001-08-21 2009-02-25 新田ゼラチン株式会社 多官能性架橋剤によって架橋したグリコサミノグリカン−コラーゲン複合体の製造法
US6906044B2 (en) * 2001-11-13 2005-06-14 Alcon, Inc. Regeneration of articular cartilage damaged by grade I and II osteoarthritis by means of the intraarticular application of a mixture of sodium hyaluronate and chondroitin sulfate in a gel vehicle
US7820194B2 (en) * 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
JP3916516B2 (ja) 2002-06-10 2007-05-16 独立行政法人物質・材料研究機構 硬組織−軟組織界面再生用足場材料
US6780366B2 (en) 2002-08-15 2004-08-24 Mentor Corporation Drip retainer
KR100523953B1 (ko) 2002-08-27 2005-10-25 주식회사 엘지생명과학 천연다당류와 히알루론산의 마이크로비드 및 이의 제조 방법
KR100507545B1 (ko) 2002-09-03 2005-08-09 주식회사 엘지생명과학 히알루론산 유도체 및 그의 제조방법
US20040127932A1 (en) 2002-09-12 2004-07-01 Shah Tilak M. Dip-molded polymeric medical devices with reverse thickness gradient, and method of making same
DE10246340A1 (de) 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
US20040101959A1 (en) 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
JP2006516202A (ja) 2002-12-30 2006-06-29 アンジオテック インターナショナル アクツィエン ゲゼルシャフト シルクステントグラフト
US20040127698A1 (en) 2002-12-31 2004-07-01 Industrial Technology Research Institute Method for producing double-crosslinked hyaluronate material
WO2004073759A1 (en) 2003-02-19 2004-09-02 Aventis Pharmaceuticals Holdings Inc. Composition and method for intradermal soft tissue augmentation
JP2006521180A (ja) 2003-03-25 2006-09-21 バイオキュア・インコーポレーテッドBiocure,Inc. ヒドロゲル糸による医療装置
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
WO2004092223A1 (en) 2003-04-17 2004-10-28 Ultraceuticals R & D Pty Limited Cross-linked polysaccharide composition
JP2004323453A (ja) 2003-04-25 2004-11-18 Chisso Corp 分解性ゲル及びその製造法
WO2004102654A1 (ja) 2003-05-13 2004-11-25 Mimasu Semiconductor Industry Co.,Ltd. ウェハ単離方法、ウェハ単離装置及びウェハ単離移載機
CA2534033A1 (fr) 2003-07-30 2005-02-10 Anteis S.A. Matrice complexe a usage biomedical
WO2005034852A3 (en) * 2003-08-26 2007-12-13 Gel Del Technologies Inc Protein biomaterials and biocoacervates and methods of making and using thereof
EP1676895B1 (en) * 2003-10-20 2013-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch for external use on skin
ES2406555T3 (es) 2003-10-29 2013-06-07 Teijin Limited Compuesto de ácido hialurónico, hidrogel del mismo y material para tratar articulaciones
WO2005051232A3 (en) 2003-11-20 2005-12-08 Angiotech Int Ag Soft tissue implants and anti-scarring agents
EP1691852A2 (en) 2003-11-10 2006-08-23 Angiotech International AG Medical implants and fibrosis-inducing agents
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US8124120B2 (en) 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
US8524213B2 (en) 2003-12-30 2013-09-03 Genzyme Corporation Polymeric materials, their preparation and use
WO2005066215A1 (en) 2003-12-30 2005-07-21 Genzyme Corporation Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
DE102004002001A1 (de) 2004-01-14 2005-08-11 Dirting, Kay, Dr. med. Mittel zur Behandlung von entzündlichen Erkrankungen
JP2007519756A (ja) 2004-01-30 2007-07-19 アンジオテック インターナショナル アーゲー 拘縮を治療するための組成物および方法
FR2865737B1 (fr) 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible
US20050226936A1 (en) 2004-04-08 2005-10-13 Q-Med Ab Method of soft tissue augmentation
US8288362B2 (en) 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods
ES2609105T3 (es) 2004-05-20 2017-04-18 Mentor Worldwide Llc Método de enlance covalente de ácido hialurónico y quitosano
EP1750769B1 (en) 2004-05-20 2013-01-23 Mentor Worldwide LLC Methods for making injectable polymer hydrogels
JP2008502690A (ja) 2004-06-15 2008-01-31 アンドリュー シァン チェン, リン脂質組成物ならびにその調製方法および使用方法
EP1781305A2 (en) 2004-08-13 2007-05-09 Angiotech International Ag Compositions and methods using hyaluronic acid and hyaluronidase inhibitors
US20060040895A1 (en) 2004-08-19 2006-02-23 Kipling Thacker Aesthetic use of hyaluronan
US7414021B2 (en) 2004-10-01 2008-08-19 Vincent Carmine Giampapa Method and composition for restoration of age related tissue loss in the face or selected areas of the body
KR100762928B1 (ko) 2004-10-29 2007-10-04 재단법인서울대학교산학협력재단 견 피브로인 나노섬유로 이루어진 부직포 형태의 골조직유도 재생용 차폐막 및 그 제조방법
US20060105022A1 (en) 2004-11-15 2006-05-18 Shiseido Co., Ltd. Process for preparing crosslinked hyaluronic acid gel
ES2636998T3 (es) 2004-11-24 2017-10-10 Albumedix A/S Método de reticulación de ácido hialurónico con divinil sulfona
FR2878444B1 (fr) 2004-11-30 2008-04-25 Corneal Ind Soc Par Actions Si Solutions viscoelastiques renfermant du hyaluronate de sodiu et de l'hydroxypropylmethylcellulose, preparation et utilisations
WO2006067608A1 (en) 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
US20060257488A1 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
EP1726299A3 (en) 2005-05-27 2007-04-18 StratoSphere Pharma AB Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
US7491709B2 (en) 2005-07-01 2009-02-17 Wayne Carey Treatment with hyaluronic acid
CN102266274B (zh) 2005-08-11 2016-05-18 株式会社林原 胶原产生增强剂及其用途
JP4982718B2 (ja) 2005-08-31 2012-07-25 株式会社林原 美肌用の経口摂取用組成物
CA2624362C (en) 2005-10-03 2015-05-26 Mark A. Pinsky Liposomes comprising collagen and their use in improved skin care
WO2007070547A3 (en) 2005-12-14 2007-08-16 Anika Therapeutics Inc Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20070202084A1 (en) 2005-12-14 2007-08-30 Anika Therapeutics, Inc. Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects
FR2894827B1 (fr) 2005-12-21 2010-10-29 Galderma Res & Dev Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation,et leurs utilisations
FR2895907B1 (fr) 2006-01-06 2012-06-01 Anteis Sa Gel viscoelastique a usage dermatologique
US20070184087A1 (en) 2006-02-06 2007-08-09 Bioform Medical, Inc. Polysaccharide compositions for use in tissue augmentation
US20070212385A1 (en) 2006-03-13 2007-09-13 David Nathaniel E Fluidic Tissue Augmentation Compositions and Methods
US20070218102A1 (en) 2006-03-15 2007-09-20 Surmodics, Inc. Biodegradable hydrophobic polysaccharide-based coatings
FR2900575B1 (fr) 2006-05-05 2008-10-17 Anteis Sa Gel biocompatible a liberation controlee, son procede de preparation et son utilisation
EP2543340A1 (en) 2006-05-19 2013-01-09 Trustees Of Boston University Novel hydrophilic polymers as medical lubricants and gels
US20070298005A1 (en) 2006-06-22 2007-12-27 Marie-Josee Thibault Injectable composition for treatment of skin defects or deformations
WO2008003321A3 (en) 2006-07-07 2008-03-13 Novozymes Biopolymer As Compositions with several hyaluronic acid fractions for cosmetic use
DE102006034529A1 (de) 2006-07-24 2008-01-31 Beiersdorf Ag Kosmetische Formulierung mit (2-Hydroxyethyl)harnstoff und Hyaluronsäure
WO2008034176A1 (en) * 2006-09-19 2008-03-27 Ultraceuticals R & D Pty Ltd Cross-linked polysaccharide gels
FR2908415B1 (fr) 2006-11-10 2009-01-23 Abr Dev Sarl Acide hyaluronique reticule et son procede de preparation
FR2909560B1 (fr) 2006-12-06 2012-12-28 Fabre Pierre Dermo Cosmetique Gel d'acide hyaluronique pour injection intradermique
WO2008072230A1 (en) * 2006-12-11 2008-06-19 Chit2Gel Ltd. Novel injectable chitosan mixtures forming hydrogels
KR100759091B1 (ko) 2006-12-13 2007-09-17 조강선 피부 충전제 조성물
WO2008077172A3 (en) 2006-12-22 2009-05-14 Croma Pharma Ges M B H Use of polymers
WO2008098007A1 (en) 2007-02-05 2008-08-14 Freedom-2, Inc. Tissue fillers and methods of using the same
US8784893B2 (en) 2007-02-05 2014-07-22 Carbylan Therapeutics, Inc. Polymer formulations for delivery of bioactive agents
US7776840B2 (en) 2007-02-21 2010-08-17 Cutanea Life Sciences, Inc. Methods of use of biomaterial and injectable implant containing biomaterial
US7939578B2 (en) 2007-02-23 2011-05-10 3M Innovative Properties Company Polymeric fibers and methods of making
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20080268051A1 (en) 2007-04-30 2008-10-30 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
CA2686505A1 (fr) 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
CA2686558A1 (fr) 2007-05-11 2008-12-11 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
CA2687990A1 (en) 2007-05-23 2008-12-04 Allergan, Inc. Cross-linked collagen and uses thereof
EP2162158A2 (en) 2007-05-23 2010-03-17 Allergan, Inc. Coated hyaluronic acid particles
WO2008157608A1 (en) 2007-06-18 2008-12-24 Cartlix, Inc. Composite scaffolds for tissue regeneration
US9011894B2 (en) 2007-06-29 2015-04-21 Carbylan Therapeutics, Inc. Sterile hyaluronic acid polymer compositions and related methods
WO2009017646A3 (en) 2007-07-27 2009-04-16 Humacyte Inc Compositions comprising human collagen and human elastin and methods for soft tissue augmentation
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US20110077737A1 (en) 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US20120071437A1 (en) 2007-07-30 2012-03-22 Allergan, Inc. Tunable crosslinked polysaccharide compositions
FR2920000B1 (fr) 2007-08-13 2010-01-29 Oreal Composition cosmetique ou pharmaceutique contenant de l'acide hyaluronique, et procede cosmetique pour diminuer les signes du vieilissement
WO2009026158A3 (en) 2007-08-16 2009-07-23 Univ Carnegie Mellon Inflammation-regulating compositions and methods
KR100813224B1 (ko) * 2007-08-24 2008-03-13 한양대학교 산학협력단 단백질 약물전달용 온도 가역성 코아세르베이트 조합 겔
FR2920968B1 (fr) 2007-09-14 2009-11-13 Oreal Procede cosmetique de traitement esthetique et/ou reparateur de la peau
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US7910134B2 (en) 2007-10-29 2011-03-22 Ayman Boutros Alloplastic injectable dermal filler and methods of use thereof
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
FR2924615B1 (fr) 2007-12-07 2010-01-22 Vivacy Lab Hydrogel cohesif biodegradable.
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
EP2222270A4 (en) 2007-12-26 2012-01-18 Mark A Pinsky Collagen formulations for improved skin care
US20090291986A1 (en) 2008-05-22 2009-11-26 Apostolos Pappas Composition and method of treating facial skin defect
US20090297632A1 (en) 2008-06-02 2009-12-03 Waugh Jacob M Device, Methods and Compositions to Alter Light Interplay with Skin
WO2010003797A1 (en) 2008-07-09 2010-01-14 Novozymes Biopharma Dk A/S Hyaluronic acid for corneal wound healing
US20110118206A1 (en) 2008-08-04 2011-05-19 Allergan Industrie, Sas Hyaluronic acid based formulations
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
EP3184552A1 (en) 2008-09-02 2017-06-28 Tautona Group LP Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
JP5702723B2 (ja) 2008-09-04 2015-04-15 ザ ジェネラル ホスピタル コーポレイション 声帯および軟組織の増強および修復用ヒドロゲル
GB0816496D0 (en) 2008-09-10 2008-10-15 Zhao Xiaobin Hyaluronic acid cryogel
EP2343078A4 (en) 2008-09-30 2012-05-16 Denki Kagaku Kogyo Kk Light-stabilized pharmaceutical composition
US20100098794A1 (en) 2008-10-17 2010-04-22 Armand Gerard Topical anti-wrinkle and anti-aging moisturizing cream
US20100111919A1 (en) 2008-10-31 2010-05-06 Tyco Healthcare Group Lp Delayed gelation compositions and methods of use
US9248165B2 (en) 2008-11-05 2016-02-02 Hancock-Jaffe Laboratories, Inc. Composite containing collagen and elastin as a dermal expander and tissue filler
CA2935819A1 (en) 2008-11-07 2010-05-14 Klox Technologies Inc. Combination of an oxidant and a photoactivator for the healing of wounds
FR2938187B1 (fr) 2008-11-07 2012-08-17 Anteis Sa Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
US8858999B2 (en) 2008-11-28 2014-10-14 Universita' Degli Studi Di Palermo Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof
US20100136070A1 (en) 2008-12-03 2010-06-03 Jakk Group, Inc. Methods, devices, and compositions for dermal filling
EP2236523A1 (en) 2009-03-30 2010-10-06 Scivision Biotech Inc. Method for producing cross-linked hyaluronic acid
DK2413894T3 (da) 2009-04-02 2017-04-03 Allergan Inc Håragtigt formede hydrogeler til forstærkning af blødvæv
US9371402B2 (en) 2009-04-09 2016-06-21 Scivision Biotech Inc. Method for producing cross-linked hyaluronic acid
US8846640B2 (en) 2009-08-27 2014-09-30 Fidia Farmaceutici S.P.A. Viscoelastic gels as novel fillers
US20110171286A1 (en) 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US20110171311A1 (en) 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
KR101764451B1 (ko) 2010-03-12 2017-08-02 알러간 인더스트리 에스에이에스 피부 상태 개선을 위한 히알루론안 폴리머 및 만니톨을 포함하는 유체 조성물
ES2585388T3 (es) 2010-03-22 2016-10-05 Allergan, Inc. Hidrogeles reticulados de polisacárido y proteína-polisacárido para aumento de tejido blando
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
WO2012054311A1 (en) 2010-10-20 2012-04-26 Tautona Group Lp Threads of cross-linked hyaluronic acid and methods of preparation and use thereof
US9299476B2 (en) 2010-10-22 2016-03-29 Newsouth Innovations Pty Limited Polymeric material
FR2968306B1 (fr) 2010-12-06 2014-02-28 Teoxane Procede de preparation d'un gel reticule
FR2968305B1 (fr) 2010-12-06 2014-02-28 Teoxane Procede de preparation d'un gel reticule
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
KR20140072008A (ko) 2011-06-03 2014-06-12 알러간, 인코포레이티드 항산화제를 포함하는 피부 충전제 조성물
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130116411A1 (en) 2011-09-06 2013-05-09 Allergan, Inc. Methods of making hyaluronic acid/collagen compositions
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US20130116190A1 (en) 2011-09-06 2013-05-09 Allergan, Inc. Hyaluronic acid-collagen matrices for tissue engineering
US20140011980A1 (en) 2012-07-03 2014-01-09 Allergan, Inc. Methods for sterilizing compositions and resulting compositions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102973592A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗糖尿病药物中的应用
CN104083396A (zh) * 2014-06-27 2014-10-08 牟国营 角膜表面保护剂及其制备方法和应用
CN104083396B (zh) * 2014-06-27 2017-07-25 牟国营 角膜表面保护剂及其制备方法和应用
CN104188819A (zh) * 2014-09-25 2014-12-10 山西医科大学 一种透明质酸分散的橙皮素纳米爽肤水及其制备方法

Also Published As

Publication number Publication date Type
EP2219595A1 (en) 2010-08-25 application
US20130209532A1 (en) 2013-08-15 application
KR20100117563A (ko) 2010-11-03 application
US8394782B2 (en) 2013-03-12 grant
US20140349959A1 (en) 2014-11-27 application
US20100004198A1 (en) 2010-01-07 application
KR101554758B1 (ko) 2015-09-21 grant
US8853184B2 (en) 2014-10-07 grant
ES2568781T3 (es) 2016-05-04 grant
RU2010125704A (ru) 2012-01-10 application
US8513216B2 (en) 2013-08-20 grant
EP3047844A1 (en) 2016-07-27 application
CA2706880A1 (en) 2009-06-11 application
WO2009073437A1 (en) 2009-06-11 application
EP2219595B1 (en) 2016-02-10 grant
JP2011505362A (ja) 2011-02-24 application
US20090143331A1 (en) 2009-06-04 application

Similar Documents

Publication Publication Date Title
Duranti et al. Injectable hyaluronic acid gel for soft tissue augmentation
Fakhari et al. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment
US20100136070A1 (en) Methods, devices, and compositions for dermal filling
US6982298B2 (en) Hydroxyphenyl cross-linked macromolecular network and applications thereof
Nobuhiko et al. Inflammation responsive degradation of crosslinked hyaluronic acid gels
Schanté et al. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications
US20110077737A1 (en) Tunably Crosslinked Polysaccharide Compositions
US20060246137A1 (en) Complex matrix for biomedical use
US20120071437A1 (en) Tunable crosslinked polysaccharide compositions
Andre Hyaluronic acid and its use as a “rejuvenation” agent in cosmetic dermatology
US20070026070A1 (en) Cross-linked polysaccharide composition
US8455465B2 (en) Heat sterilised injectable composition of hyaluronic acid or one of the salts thereof, polyols and lidocaine
Kogan et al. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications
Weindl et al. Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects
US20120190644A1 (en) Viscoelastic gels as novel fillers
Liao et al. Hyaluronan: pharmaceutical characterization and drug delivery
WO2010029344A2 (en) Hyaluronic acid cryogel
WO1996033751A1 (fr) Compositions biphasiques injectables renfermant de l'acide hyaluronique, notamment utiles en chirurgies reparatrice et esthetique
US20090155362A1 (en) Method of cross-linking hyaluronic acid with divinulsulfone
US8052990B2 (en) Biocompatible crosslinked gel
WO1999031167A1 (en) Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US20110172180A1 (en) Heat stable hyaluronic acid compositions for dermatological use
US20130244972A1 (en) Injectable chitosan mixtures forming hydrogels
US20110171286A1 (en) Hyaluronic acid compositions for dermatological use
US20060293277A1 (en) Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making for making them

Legal Events

Date Code Title Description
C06 Publication
C10 Request of examination as to substance
C12 Rejection of an application for a patent